WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that it has begun a pivotal registration study of its first-in-class vascular disrupting agent, ZYBRESTAT™ (combretastatin-A4 phosphate / CA4P), in patients with metastatic anaplastic thyroid cancer (ATC).